

**The CD4 T-cell Guidelines Consensus Meeting
November 14-15, Orlando, Florida**

TENTATIVE SCHEDULE

Day One

8:30-9:00

Introduction:

Jan Nicholson

Where we have been, where we are now, where we are going in CD4 cell testing. History of CDC guideline development and their impact. The process for revision for year 2002.

Moderator:

Frank Mandy

9:00-9:30

Quality Assurance Programs (MPEP):

Barbara Slade

What do we know about how well laboratories in the US are performing CD4 and CD8 cell testing?

9:30-10:00

Gating Strategies for T-cell Subsets have Evolved:

Frank Mandy

Concepts of gating and selection criteria have changed: Pros and cons of homogeneous vs. heterogeneous gating.

10:00-10:30

BREAK

Moderator:

Carol Schnizlein-Bick

10:30-11:00

One platform for absolute counting (Part One)

Mo O'Gorman

Absolute cell counting using Flow Count beads; 2- vs. 3- vs. 4-color immunophenotyping: intra and interlaboratory variability.

11:00-11:30

One platform for absolute counting (Part Two)

Carol Schnizlein-Bick

Absolute cell counting TruCount beads; 3- vs. 4-color immunophenotyping: intra and interlaboratory variability.

11:30-12:00

Quality Assurance Programs for CD4 T-cells for ACTG

Becky Gelman

What have we learned from the ACTG QAP about CD4 T-cell testing? What value does CD45 gating bring to laboratory results?

12:00-12:30

QUESTION AND ANSWERS SESSION FOR ALL MORNING SPEAKERS

12:30-2:00

LUNCH

Day One (continued)

2:00-3:45

PARALLEL WORKSHOPS

Workshop Group A

Absolute cell counting using FlowCount fluorospheres

Beckman Coulter

Workshop Group B

Absolute cell counting using TruCount fluorospheres

Becton Dickinson

Moderator:

Chris Tsoukas

3:45-4:15

T-cell subset analysis from a clinician's perspective

Chris Tsoukas

The CD4 T-cell legend is not the full story.

4:15-5:00

ORAL PRESENTATIONS (ten minutes each)

Selected from submitted abstracts (4 or 5)

Day Two

Moderator:

Mo O'Gorman

8:00-8:30

Issues of compensation, how to succeed with 3 or 4 colors?

Mario Roederer

Software versus hardware compensation in the 21st century

8:30-9:00

Has the single tube assay arrived?

Mo O'Gorman

Can one get the same results from 1 tube as from multiple tubes? Considerations for increasing the number of antibodies per tube: technical requirements for antibody combinations; quality control issues. Are isotype controls needed for CD4 and CD8 T-cell determinations?

9:00-9:30

Percentage and absolute T-cell subsets are no longer two solitudes

Michael Lederman

During clinical evaluation of HIV infection the benefits of using CD4 and CD8 percentages and absolute number values.

9:30-10:00

BREAK

Moderator:

Howard Shapiro

10:00-10:30

Quality control systems for immunophenotyping

Katharine Muirhead

Methods available for quality control and quality assurance. How are these applied in single-platform technologies and multicolor panels?

10:30-11:00

Quality Assessment issues in the Global Village

Michele Bergeron

We have the tools, are we implementing them where they are needed the most?

Day Two (continued)

11:00-11:30

Clinical cytometers moved from the floor to the desktop where next?

Howard Shapiro

Emerging new technologies that will improve or replace current clinical diagnostic tools to fight HIV disease.

11:30-12:00

QUESTIONS AND ANSWER SESSION FOR ALL MORNING SPEAKERS

12:00-12:15

Closing remarks

Jan Nicholson